Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan.
Department of Thoracic Surgery, Hyogo Collage of Medicine, Nishinomiya, Japan
Anticancer Res. 2019 Nov;39(11):6241-6247. doi: 10.21873/anticanres.13833.
BACKGROUND/AIM: We performed multimodality therapy comprising preoperative chemotherapy, extrapleural pneumonectomy (EPP), and radiation therapy for patients with malignant pleural mesothelioma (MPM). Although multimodality therapy resulted in good prognosis, further improvement is required. Therefore, herein, we analysed the prognostic factors using surgical specimens and searched for suitable molecular targets to improve the prognosis after multidisciplinary treatment.
Forty-six patients with MPM underwent multimodality therapy. Paraffin-embedded surgical samples were used for immunohistochemistry to evaluate the expression of phosphorylated (p-) AKT, extracellular signal-regulated kinase (ERK), mammalian target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK), eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and S6 ribosomal protein (S6RP).
On univariate and multivariate analyses, significant differences were observed according to the histological type, pathological stage, and p-mTOR expression rate.
The prognosis of MPM is affected by p-mTOR expression, suggesting that molecular-targeted treatment might be used during multimodal therapy for MPM.
背景/目的：我们对恶性胸膜间皮瘤（MPM）患者实施了包括术前化疗、胸膜外全肺切除术（EPP）和放射治疗在内的多模态治疗。尽管多模态治疗带来了良好的预后，但仍需要进一步改善。因此，在此，我们通过手术标本分析了预后因素，并寻找合适的分子靶点，以改善多学科治疗后的预后。
46 名 MPM 患者接受了多模态治疗。使用石蜡包埋的手术样本进行免疫组织化学分析，以评估磷酸化（p-）AKT、细胞外信号调节激酶（ERK）、雷帕霉素靶蛋白（mTOR）、丝裂原活化蛋白激酶（MAPK）、真核翻译起始因子 4E 结合蛋白 1（4E-BP1）和 S6 核糖体蛋白（S6RP）的表达。
单因素和多因素分析显示，组织学类型、病理分期和 p-mTOR 表达率有显著差异。
MPM 的预后受 p-mTOR 表达的影响，提示在 MPM 的多模态治疗中可能使用分子靶向治疗。
